ROIV — Roivant Sciences Cashflow Statement
0.000.00%
Last trade - 00:00- $8.13bn
- $2.51bn
- $124.80m
- 46
- 72
- 48
- 55
Annual cashflow statement for Roivant Sciences, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 1,010 | -900 | -924 | -1,115 | 4,231 |
| Depreciation | |||||
| Non-Cash Items | -1,816 | 263 | 217 | 247 | -5,038 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 47.1 | 85.1 | 29.5 | 6.34 | 19 |
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -759 | -552 | -678 | -843 | -765 |
| Capital Expenditures | -4.92 | -5.81 | -17.4 | -12.7 | -1.38 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 1,700 | -25.9 | 321 | -31.6 | 5,205 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 1,695 | -31.7 | 303 | -44.3 | 5,204 |
| Financing Cash Flow Items | 98.2 | -0.286 | 292 | -13.1 | -43.7 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 214 | 456 | 307 | 499 | 419 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 1,150 | -128 | -67.6 | -382 | 4,858 |